In addition, GV seems to be a better predictive factor of mid-term MACE than worsening renal failure and BNP in diabetic patients with AHF, whereas these markers usually provide robust prognostic information in all patients with AHF [32,33]. The gene discussed is NPPB; the disease is Renal insufficiency.